Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Asian Markets

Berkshire Hathaway Concludes 17-Year BYD Investment with Complete Exit

Robert Sasse by Robert Sasse
September 22, 2025
in Asian Markets, Automotive & E-Mobility, Mergers & Acquisitions
0
BYD Stock
0
SHARES
121
VIEWS
Share on FacebookShare on Twitter

Warren Buffett’s Berkshire Hathaway has liquidated its entire stake in Chinese electric vehicle manufacturer BYD, concluding a remarkable investment journey that generated returns exceeding 3,800% over nearly two decades. This move places immediate pressure on the company’s shares while raising questions about broader underlying challenges.

Berkshire’s energy subsidiary now reports a zero-dollar valuation for its BYD holding, which had been worth $415 million as recently as late 2024. The original investment dates back to September 2008, when Berkshire acquired approximately 225 million shares for $230 million—representing a 10% stake in the company following a recommendation from the late Charlie Munger.

Immediate Market Reaction and Trading Impact

Financial markets responded swiftly to the divestment news. BYD’s Hong Kong-listed shares plummeted as much as 3.6% during the trading session, ranking among the poorest performers within China’s stock indices. The stock ultimately closed at HK$110.50, marking a noticeable decline from the previous HK$113.50 level.

Key market response metrics included:
– Intraday decline reaching 3.6% on the Hong Kong exchange
– Trading volume surging to 12.7 million shares
– Several billion dollars erased from market capitalization

Operational Challenges Compound Pressures

While Buffett’s exit captures headlines, BYD faces multiple operational difficulties that extend beyond this ownership change. The automaker recently reduced its annual delivery target by as much as 16%, establishing a new goal of 4.6 million vehicles.

The company’s domestic markets, which contribute almost 80% of total revenue, have contracted for four consecutive months. Quarterly profits declined for the first time in three and a half years, falling substantially short of analyst expectations.

Should investors sell immediately? Or is it worth buying BYD?

Through July, BYD managed to sell just 2.49 million vehicles—representing only 45% of its already-reduced annual target of 5.5 million units. Even these lowered expectations appear challenging to achieve.

European Expansion Provides Silver Lining

Amid domestic struggles, BYD demonstrates impressive progress in European markets. The company captured 10% market share in Spain during July 2025—double the European average and exceeding Tesla’s performance in that market.

This success stems from an aggressive pricing strategy. The BYD Seal U DM-I starts at approximately €30,000 in Spain, while comparable plug-in hybrid models from Volkswagen and Peugeot exceed €40,000.

Implications of Berkshire’s Complete Divestment

The full exit eliminates an overhang that has weighed on BYD’s stock since 2022, when Berkshire initiated its gradual position reduction. Each previous sales announcement had created renewed uncertainty among investors.

BYD management responded with diplomatic appreciation, thanking Berkshire for “investment, assistance, and partnership over the past 17 years”—an indication that the complete divestment did not come as a surprise internally.

While the removal of persistent selling pressure may provide short-term relief for the stock, BYD’s fundamental business challenges remain the primary concern for investors moving forward.

Ad

BYD Stock: Buy or Sell?! New BYD Analysis from February 8 delivers the answer:

The latest BYD figures speak for themselves: Urgent action needed for BYD investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

BYD: Buy or sell? Read more here...

Tags: BYD
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Potbelly Stock
Analysis

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026
Next Post
Rheinmetall Stock

Strategic Naval Acquisition Positions Rheinmetall for Broader Defense Dominance

Valneva Stock

Valneva Shares Face Regulatory Setback Despite Promising Pipeline

Deutz AG Stock

Defense Sector Momentum Could Propel Deutz AG's Strategic Growth

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com